Extracellular vesicles as a platform for membrane-associated therapeutic protein delivery

被引:206
作者
Yang, Yoosoo [1 ,2 ]
Hong, Yeonsun [1 ,3 ]
Cho, Eunji [1 ,3 ]
Kim, Gi Beom [1 ,3 ]
Kim, In-San [1 ,3 ]
机构
[1] Korea Inst Sci & Technol, Biomed Res Inst, Seoul, South Korea
[2] Korea Univ Sci & Technol, Div Biomed Sci & Technol, KIST Sch, Seoul, South Korea
[3] Korea Univ, KU KIST Grad Sch Converging Sci & Technol, Seoul, South Korea
基金
新加坡国家研究基金会;
关键词
Extracellular vesicle; Exosomes; Membrane protein; Microdomain; Protein therapeutics; CELL-DERIVED EXOSOMES; PEPTIDE-BASED VACCINE; DRUG-DELIVERY; GENE-THERAPY; MEDIATED DELIVERY; PENETRATING PEPTIDES; TUMOR-ANTIGENS; IN-VITRO; INSERTIONAL ONCOGENESIS; INTRACELLULAR DELIVERY;
D O I
10.1080/20013078.2018.1440131
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Membrane proteins are of great research interest, particularly because they are rich in targets for therapeutic application. The suitability of various membrane proteins as targets for therapeutic formulations, such as drugs or antibodies, has been studied in preclinical and clinical studies. For therapeutic application, however, a protein must be expressed and purified in as close to its native conformation as possible. This has proven difficult for membrane proteins, as their native conformation requires the association with an appropriate cellular membrane. One solution to this problem is to use extracellular vesicles as a display platform. Exosomes and microvesicles are membranous extracellular vesicles that are released from most cells. Their membranes may provide a favourable microenvironment for membrane proteins to take on their proper conformation, activity, and membrane distribution; moreover, membrane proteins can cluster into microdomains on the surface of extracellular vesicles following their biogenesis. In this review, we survey the state-of-the-art of extracellular vesicle (exosome and small-sized microvesicle)-based therapeutics, evaluate the current biological understanding of these formulations, and forecast the technical advances that will be needed to continue driving the development of membrane protein therapeutics.
引用
收藏
页数:15
相关论文
共 187 条
[1]   Gene transfer into muscle by electroporation in vivo [J].
Aihara, H ;
Miyazaki, J .
NATURE BIOTECHNOLOGY, 1998, 16 (09) :867-870
[2]   Liposome: classification, preparation, and applications [J].
Akbarzadeh, Abolfazl ;
Rezaei-Sadabady, Rogaie ;
Davaran, Soodabeh ;
Joo, Sang Woo ;
Zarghami, Nosratollah ;
Hanifehpour, Younes ;
Samiei, Mohammad ;
Kouhi, Mohammad ;
Nejati-Koshki, Kazem .
NANOSCALE RESEARCH LETTERS, 2013, 8
[3]   Intercellular transfer of the oncogenic receptor EGFrvIII by microvesicles derived from tumour cells [J].
Al-Nedawi, Khalid ;
Meehan, Brian ;
Micallef, Johann ;
Lhotak, Vladimir ;
May, Linda ;
Guha, Abhijit ;
Rak, Janusz .
NATURE CELL BIOLOGY, 2008, 10 (05) :619-U24
[4]   GRecon: A Method for the Lipid Reconstitution of Membrane Proteins [J].
Althoff, Thorsten ;
Davies, Karen M. ;
Schulze, Sabrina ;
Joos, Friederike ;
Kuehlbrandt, Werner .
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, 2012, 51 (33) :8343-8347
[5]   Exosomes from plasmacytoma cells as a tumor vaccine [J].
Altieri, SL ;
Khan, ANH ;
Tomasi, TB .
JOURNAL OF IMMUNOTHERAPY, 2004, 27 (04) :282-288
[6]   Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes [J].
Alvarez-Erviti, Lydia ;
Seow, Yiqi ;
Yin, HaiFang ;
Betts, Corinne ;
Lakhal, Samira ;
Wood, Matthew J. A. .
NATURE BIOTECHNOLOGY, 2011, 29 (04) :341-U179
[7]   Exosomes as potent cell-free peptide-based vaccine.: I.: Dendritic cell-derived exosomes transfer functional MHC class I/peptide complexes to dendritic cells [J].
André, F ;
Chaput, N ;
Schartz, NEC ;
Flament, C ;
Aubert, N ;
Bernard, J ;
Lemonnier, F ;
Raposo, G ;
Escudier, B ;
Hsu, DH ;
Tursz, T ;
Amigorena, S ;
Angevin, E ;
Zitvogel, L .
JOURNAL OF IMMUNOLOGY, 2004, 172 (04) :2126-2136
[8]   Tumor-derived exosomes:: a new source of tumor rejection antigens [J].
André, F ;
Scharz, NEC ;
Chaput, N ;
Flament, C ;
Raposo, G ;
Amigorena, S ;
Angevin, E ;
Zitvogel, L .
VACCINE, 2002, 20 :A28-A31
[9]  
[Anonymous], J PARAMED SCI
[10]  
Antes T.J., 2015, U.S. Patent, Patent No. [US9005888B2, 9005888]